Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring Article Swipe
Tyler Brady
,
Tianhui Zhang
,
Kevin M. Tuffy
,
Nantaporn Haskins
,
Qun Du
,
Jia Lin
,
Gilad Kaplan
,
Steven Novick
,
Tiffany Barnes
,
Kuishu Ren
,
Kim Rosenthal
,
Patrick M. McTamney
,
Michael E. Abram
,
Katie Streicher
,
Elizabeth J. Kelly
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1128/spectrum.01034-22
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1128/spectrum.01034-22
SARS-CoV-2 variants harbor multiple substitutions in their spike trimers, potentially leading to breakthrough infections and clinical resistance to immune therapies. For this reason, a BLI assay was developed and qualified to evaluate the reliability of screening SARS-CoV-2 spike trimer variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralization susceptibility verification testing.
Related Topics
Concepts
Trimer
Monoclonal antibody
Neutralization
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Coronavirus disease 2019 (COVID-19)
Virology
Antibody
2019-20 coronavirus outbreak
Computational biology
Immunology
Biology
Medicine
Chemistry
Internal medicine
Outbreak
Dimer
Organic chemistry
Disease
Infectious disease (medical specialty)
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1128/spectrum.01034-22
- OA Status
- gold
- Cited By
- 6
- References
- 33
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4292608643
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4292608643Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1128/spectrum.01034-22Digital Object Identifier
- Title
-
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance MonitoringWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-08-22Full publication date if available
- Authors
-
Tyler Brady, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany Barnes, Kuishu Ren, Kim Rosenthal, Patrick M. McTamney, Michael E. Abram, Katie Streicher, Elizabeth J. KellyList of authors in order
- Landing page
-
https://doi.org/10.1128/spectrum.01034-22Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1128/spectrum.01034-22Direct OA link when available
- Concepts
-
Trimer, Monoclonal antibody, Neutralization, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19), Virology, Antibody, 2019-20 coronavirus outbreak, Computational biology, Immunology, Biology, Medicine, Chemistry, Internal medicine, Outbreak, Dimer, Organic chemistry, Disease, Infectious disease (medical specialty)Top concepts (fields/topics) attached by OpenAlex
- Cited by
-
6Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2, 2024: 2, 2023: 1, 2022: 1Per-year citation counts (last 5 years)
- References (count)
-
33Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4292608643 |
|---|---|
| doi | https://doi.org/10.1128/spectrum.01034-22 |
| ids.doi | https://doi.org/10.1128/spectrum.01034-22 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35993765 |
| ids.openalex | https://openalex.org/W4292608643 |
| fwci | 0.75109077 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D064370 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Spike Glycoprotein, Coronavirus |
| mesh[2].qualifier_ui | Q000235 |
| mesh[2].descriptor_ui | D000086402 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | genetics |
| mesh[2].descriptor_name | SARS-CoV-2 |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D015203 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Reproducibility of Results |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D000911 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Antibodies, Monoclonal |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D057134 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Antibodies, Neutralizing |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000914 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Antibodies, Viral |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D007368 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Interferometry |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D007128 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Immunoglobulin Fragments |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D011994 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Recombinant Proteins |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D000093485 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | COVID-19 Drug Treatment |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D006801 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Humans |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D064370 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Spike Glycoprotein, Coronavirus |
| mesh[13].qualifier_ui | Q000235 |
| mesh[13].descriptor_ui | D000086402 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | genetics |
| mesh[13].descriptor_name | SARS-CoV-2 |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D015203 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Reproducibility of Results |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D000911 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Antibodies, Monoclonal |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D057134 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Antibodies, Neutralizing |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000914 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Antibodies, Viral |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D007368 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Interferometry |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D007128 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Immunoglobulin Fragments |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D011994 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Recombinant Proteins |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000093485 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | COVID-19 Drug Treatment |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D006801 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Humans |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D064370 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Spike Glycoprotein, Coronavirus |
| mesh[24].qualifier_ui | Q000235 |
| mesh[24].descriptor_ui | D000086402 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | genetics |
| mesh[24].descriptor_name | SARS-CoV-2 |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D015203 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Reproducibility of Results |
| mesh[26].qualifier_ui | Q000627 |
| mesh[26].descriptor_ui | D000911 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | therapeutic use |
| mesh[26].descriptor_name | Antibodies, Monoclonal |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D057134 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Antibodies, Neutralizing |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D000914 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Antibodies, Viral |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D007368 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Interferometry |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D007128 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Immunoglobulin Fragments |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D011994 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Recombinant Proteins |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D000093485 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | COVID-19 Drug Treatment |
| type | article |
| title | Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring |
| biblio.issue | 5 |
| biblio.volume | 10 |
| biblio.last_page | e0103422 |
| biblio.first_page | e0103422 |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T11754 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.992900013923645 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | SARS-CoV-2 detection and testing |
| topics[2].id | https://openalex.org/T10041 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9878000020980835 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | COVID-19 Clinical Research Studies |
| is_xpac | False |
| apc_list.value | 2500 |
| apc_list.currency | USD |
| apc_list.value_usd | 2500 |
| apc_paid.value | 2500 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2500 |
| concepts[0].id | https://openalex.org/C2776403692 |
| concepts[0].level | 3 |
| concepts[0].score | 0.672722339630127 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q898416 |
| concepts[0].display_name | Trimer |
| concepts[1].id | https://openalex.org/C542903549 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6541116833686829 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q422248 |
| concepts[1].display_name | Monoclonal antibody |
| concepts[2].id | https://openalex.org/C14086860 |
| concepts[2].level | 3 |
| concepts[2].score | 0.616436243057251 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q337120 |
| concepts[2].display_name | Neutralization |
| concepts[3].id | https://openalex.org/C3007834351 |
| concepts[3].level | 5 |
| concepts[3].score | 0.552728533744812 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q82069695 |
| concepts[3].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| concepts[4].id | https://openalex.org/C3008058167 |
| concepts[4].level | 4 |
| concepts[4].score | 0.49883294105529785 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[4].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[5].id | https://openalex.org/C159047783 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4908760190010071 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[5].display_name | Virology |
| concepts[6].id | https://openalex.org/C159654299 |
| concepts[6].level | 2 |
| concepts[6].score | 0.45300471782684326 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[6].display_name | Antibody |
| concepts[7].id | https://openalex.org/C3006700255 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4129524827003479 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q81068910 |
| concepts[7].display_name | 2019-20 coronavirus outbreak |
| concepts[8].id | https://openalex.org/C70721500 |
| concepts[8].level | 1 |
| concepts[8].score | 0.4102155566215515 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q177005 |
| concepts[8].display_name | Computational biology |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3538840413093567 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C86803240 |
| concepts[10].level | 0 |
| concepts[10].score | 0.35221612453460693 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[10].display_name | Biology |
| concepts[11].id | https://openalex.org/C71924100 |
| concepts[11].level | 0 |
| concepts[11].score | 0.3187110424041748 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[11].display_name | Medicine |
| concepts[12].id | https://openalex.org/C185592680 |
| concepts[12].level | 0 |
| concepts[12].score | 0.27182477712631226 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[12].display_name | Chemistry |
| concepts[13].id | https://openalex.org/C126322002 |
| concepts[13].level | 1 |
| concepts[13].score | 0.13203638792037964 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[13].display_name | Internal medicine |
| concepts[14].id | https://openalex.org/C116675565 |
| concepts[14].level | 2 |
| concepts[14].score | 0.07544013857841492 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q3241045 |
| concepts[14].display_name | Outbreak |
| concepts[15].id | https://openalex.org/C2779546866 |
| concepts[15].level | 2 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q531306 |
| concepts[15].display_name | Dimer |
| concepts[16].id | https://openalex.org/C178790620 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[16].display_name | Organic chemistry |
| concepts[17].id | https://openalex.org/C2779134260 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[17].display_name | Disease |
| concepts[18].id | https://openalex.org/C524204448 |
| concepts[18].level | 3 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[18].display_name | Infectious disease (medical specialty) |
| keywords[0].id | https://openalex.org/keywords/trimer |
| keywords[0].score | 0.672722339630127 |
| keywords[0].display_name | Trimer |
| keywords[1].id | https://openalex.org/keywords/monoclonal-antibody |
| keywords[1].score | 0.6541116833686829 |
| keywords[1].display_name | Monoclonal antibody |
| keywords[2].id | https://openalex.org/keywords/neutralization |
| keywords[2].score | 0.616436243057251 |
| keywords[2].display_name | Neutralization |
| keywords[3].id | https://openalex.org/keywords/severe-acute-respiratory-syndrome-coronavirus-2 |
| keywords[3].score | 0.552728533744812 |
| keywords[3].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| keywords[4].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[4].score | 0.49883294105529785 |
| keywords[4].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[5].id | https://openalex.org/keywords/virology |
| keywords[5].score | 0.4908760190010071 |
| keywords[5].display_name | Virology |
| keywords[6].id | https://openalex.org/keywords/antibody |
| keywords[6].score | 0.45300471782684326 |
| keywords[6].display_name | Antibody |
| keywords[7].id | https://openalex.org/keywords/2019-20-coronavirus-outbreak |
| keywords[7].score | 0.4129524827003479 |
| keywords[7].display_name | 2019-20 coronavirus outbreak |
| keywords[8].id | https://openalex.org/keywords/computational-biology |
| keywords[8].score | 0.4102155566215515 |
| keywords[8].display_name | Computational biology |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.3538840413093567 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/biology |
| keywords[10].score | 0.35221612453460693 |
| keywords[10].display_name | Biology |
| keywords[11].id | https://openalex.org/keywords/medicine |
| keywords[11].score | 0.3187110424041748 |
| keywords[11].display_name | Medicine |
| keywords[12].id | https://openalex.org/keywords/chemistry |
| keywords[12].score | 0.27182477712631226 |
| keywords[12].display_name | Chemistry |
| keywords[13].id | https://openalex.org/keywords/internal-medicine |
| keywords[13].score | 0.13203638792037964 |
| keywords[13].display_name | Internal medicine |
| keywords[14].id | https://openalex.org/keywords/outbreak |
| keywords[14].score | 0.07544013857841492 |
| keywords[14].display_name | Outbreak |
| language | en |
| locations[0].id | doi:10.1128/spectrum.01034-22 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764766708 |
| locations[0].source.issn | 2165-0497 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2165-0497 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Microbiology Spectrum |
| locations[0].source.host_organization | https://openalex.org/P4310320263 |
| locations[0].source.host_organization_name | American Society for Microbiology |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320263 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Microbiology Spectrum |
| locations[0].landing_page_url | https://doi.org/10.1128/spectrum.01034-22 |
| locations[1].id | pmid:35993765 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Microbiology spectrum |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35993765 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:9704045 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Microbiol Spectr |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9704045 |
| locations[3].id | pmh:oai:doaj.org/article:98d4176648a242c59e666ffdfbd7fce6 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | cc-by-sa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Microbiology Spectrum, Vol 10, Iss 5 (2022) |
| locations[3].landing_page_url | https://doaj.org/article/98d4176648a242c59e666ffdfbd7fce6 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5025192265 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Tyler Brady |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[0].affiliations[0].raw_affiliation_string | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[0].institutions[0].ror | https://ror.org/043cec594 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | AstraZeneca (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Tyler Brady |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[1].author.id | https://openalex.org/A5071259267 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5162-5751 |
| authorships[1].author.display_name | Tianhui Zhang |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[1].affiliations[0].raw_affiliation_string | Data Sciences and Quantitative Biology, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[1].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[1].institutions[0].ror | https://ror.org/043cec594 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | AstraZeneca (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Tianhui Zhang |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Data Sciences and Quantitative Biology, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[2].author.id | https://openalex.org/A5019567842 |
| authorships[2].author.orcid | https://orcid.org/0009-0007-8644-5025 |
| authorships[2].author.display_name | Kevin M. Tuffy |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[2].affiliations[0].raw_affiliation_string | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[2].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[2].institutions[0].ror | https://ror.org/043cec594 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | AstraZeneca (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kevin M. Tuffy |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[3].author.id | https://openalex.org/A5071901424 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Nantaporn Haskins |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[3].affiliations[0].raw_affiliation_string | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[3].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[3].institutions[0].ror | https://ror.org/043cec594 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | AstraZeneca (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Nantaporn Haskins |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[4].author.id | https://openalex.org/A5102007217 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-8239-0927 |
| authorships[4].author.display_name | Qun Du |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[4].affiliations[0].raw_affiliation_string | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[4].institutions[0].ror | https://ror.org/043cec594 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | AstraZeneca (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Qun Du |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[5].author.id | https://openalex.org/A5108706020 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Jia Lin |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[5].affiliations[0].raw_affiliation_string | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[5].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[5].institutions[0].ror | https://ror.org/043cec594 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | AstraZeneca (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Jia Lin |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[6].author.id | https://openalex.org/A5032863821 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-1374-305X |
| authorships[6].author.display_name | Gilad Kaplan |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[6].affiliations[0].raw_affiliation_string | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[6].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[6].institutions[0].ror | https://ror.org/043cec594 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | AstraZeneca (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Gilad Kaplan |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Biologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[7].author.id | https://openalex.org/A5042841642 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8760-1519 |
| authorships[7].author.display_name | Steven Novick |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[7].affiliations[0].raw_affiliation_string | Data Sciences and Quantitative Biology, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[7].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[7].institutions[0].ror | https://ror.org/043cec594 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | AstraZeneca (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Steven Novick |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Data Sciences and Quantitative Biology, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[8].author.id | https://openalex.org/A5049692557 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-5995-0495 |
| authorships[8].author.display_name | Tiffany Barnes |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[8].affiliations[0].raw_affiliation_string | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[8].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[8].institutions[0].ror | https://ror.org/043cec594 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | AstraZeneca (United States) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Tiffany L. Roe |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[9].author.id | https://openalex.org/A5049559203 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-9634-3256 |
| authorships[9].author.display_name | Kuishu Ren |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[9].affiliations[0].raw_affiliation_string | Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[9].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[9].institutions[0].ror | https://ror.org/043cec594 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | AstraZeneca (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Kuishu Ren |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[10].author.id | https://openalex.org/A5112152761 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Kim Rosenthal |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[10].affiliations[0].raw_affiliation_string | Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[10].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[10].institutions[0].ror | https://ror.org/043cec594 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | AstraZeneca (United States) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Kim Rosenthal |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[11].author.id | https://openalex.org/A5109437586 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Patrick M. McTamney |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[11].affiliations[0].raw_affiliation_string | Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[11].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[11].institutions[0].ror | https://ror.org/043cec594 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | AstraZeneca (United States) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Patrick M. McTamney |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[12].author.id | https://openalex.org/A5064719195 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-6505-7281 |
| authorships[12].author.display_name | Michael E. Abram |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[12].affiliations[0].raw_affiliation_string | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[12].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[12].institutions[0].ror | https://ror.org/043cec594 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | AstraZeneca (United States) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Michael E. Abram |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[13].author.id | https://openalex.org/A5082831559 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-1684-2301 |
| authorships[13].author.display_name | Katie Streicher |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[13].affiliations[0].raw_affiliation_string | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[13].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[13].institutions[0].ror | https://ror.org/043cec594 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | AstraZeneca (United States) |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Katie Streicher |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[14].author.id | https://openalex.org/A5070656676 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-6988-8576 |
| authorships[14].author.display_name | Elizabeth J. Kelly |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210150756 |
| authorships[14].affiliations[0].raw_affiliation_string | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| authorships[14].institutions[0].id | https://openalex.org/I4210150756 |
| authorships[14].institutions[0].ror | https://ror.org/043cec594 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I105036370, https://openalex.org/I4210150756 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | AstraZeneca (United States) |
| authorships[14].author_position | last |
| authorships[14].raw_author_name | Elizabeth J. Kelly |
| authorships[14].is_corresponding | True |
| authorships[14].raw_affiliation_strings | Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1128/spectrum.01034-22 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W1977119850, https://openalex.org/W3040004795, https://openalex.org/W4200329650, https://openalex.org/W3127156785, https://openalex.org/W3009669391, https://openalex.org/W4206669628, https://openalex.org/W4205317059, https://openalex.org/W3005417802, https://openalex.org/W3084498529, https://openalex.org/W3171943759 |
| cited_by_count | 6 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 1 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1128/spectrum.01034-22 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764766708 |
| best_oa_location.source.issn | 2165-0497 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2165-0497 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Microbiology Spectrum |
| best_oa_location.source.host_organization | https://openalex.org/P4310320263 |
| best_oa_location.source.host_organization_name | American Society for Microbiology |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320263 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Microbiology Spectrum |
| best_oa_location.landing_page_url | https://doi.org/10.1128/spectrum.01034-22 |
| primary_location.id | doi:10.1128/spectrum.01034-22 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764766708 |
| primary_location.source.issn | 2165-0497 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2165-0497 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Microbiology Spectrum |
| primary_location.source.host_organization | https://openalex.org/P4310320263 |
| primary_location.source.host_organization_name | American Society for Microbiology |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320263 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Microbiology Spectrum |
| primary_location.landing_page_url | https://doi.org/10.1128/spectrum.01034-22 |
| publication_date | 2022-08-22 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W3001897055, https://openalex.org/W3038261609, https://openalex.org/W3016044084, https://openalex.org/W3046463683, https://openalex.org/W3108980364, https://openalex.org/W4233631061, https://openalex.org/W3042323010, https://openalex.org/W3199394546, https://openalex.org/W3196980779, https://openalex.org/W3163785571, https://openalex.org/W3042833857, https://openalex.org/W3133782701, https://openalex.org/W3170724610, https://openalex.org/W1999228474, https://openalex.org/W3142246475, https://openalex.org/W3129558828, https://openalex.org/W3131995220, https://openalex.org/W3133980772, https://openalex.org/W3175562186, https://openalex.org/W3037768977, https://openalex.org/W3044914269, https://openalex.org/W2750464792, https://openalex.org/W3133484407, https://openalex.org/W2074712481, https://openalex.org/W3199073977, https://openalex.org/W3086119226, https://openalex.org/W2024798162, https://openalex.org/W3202046790, https://openalex.org/W3112028440, https://openalex.org/W3007643904, https://openalex.org/W3207691699, https://openalex.org/W3215800873, https://openalex.org/W2884623540 |
| referenced_works_count | 33 |
| abstract_inverted_index.a | 23 |
| abstract_inverted_index.in | 5, 54 |
| abstract_inverted_index.of | 34, 50 |
| abstract_inverted_index.to | 11, 17, 30, 53 |
| abstract_inverted_index.BLI | 24 |
| abstract_inverted_index.For | 20 |
| abstract_inverted_index.and | 14, 28, 46 |
| abstract_inverted_index.the | 32, 48 |
| abstract_inverted_index.was | 26 |
| abstract_inverted_index.this | 21 |
| abstract_inverted_index.assay | 25 |
| abstract_inverted_index.prior | 52 |
| abstract_inverted_index.spike | 7, 37 |
| abstract_inverted_index.their | 6 |
| abstract_inverted_index.vitro | 55 |
| abstract_inverted_index.(MAbs) | 44 |
| abstract_inverted_index.harbor | 2 |
| abstract_inverted_index.immune | 18 |
| abstract_inverted_index.trimer | 38 |
| abstract_inverted_index.against | 40 |
| abstract_inverted_index.leading | 10 |
| abstract_inverted_index.reason, | 22 |
| abstract_inverted_index.AZD7442, | 51 |
| abstract_inverted_index.clinical | 15 |
| abstract_inverted_index.evaluate | 31 |
| abstract_inverted_index.multiple | 3 |
| abstract_inverted_index.testing. | 60 |
| abstract_inverted_index.trimers, | 8 |
| abstract_inverted_index.variants | 1, 39 |
| abstract_inverted_index.developed | 27 |
| abstract_inverted_index.qualified | 29 |
| abstract_inverted_index.screening | 35 |
| abstract_inverted_index.SARS-CoV-2 | 0, 36 |
| abstract_inverted_index.antibodies | 43 |
| abstract_inverted_index.components | 49 |
| abstract_inverted_index.infections | 13 |
| abstract_inverted_index.monoclonal | 42 |
| abstract_inverted_index.resistance | 16 |
| abstract_inverted_index.therapies. | 19 |
| abstract_inverted_index.cilgavimab, | 47 |
| abstract_inverted_index.potentially | 9 |
| abstract_inverted_index.pseudovirus | 56 |
| abstract_inverted_index.reliability | 33 |
| abstract_inverted_index.tixagevimab | 45 |
| abstract_inverted_index.breakthrough | 12 |
| abstract_inverted_index.verification | 59 |
| abstract_inverted_index.substitutions | 4 |
| abstract_inverted_index.neutralization | 57 |
| abstract_inverted_index.susceptibility | 58 |
| abstract_inverted_index.anti-SARS-CoV-2 | 41 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5070656676 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 15 |
| corresponding_institution_ids | https://openalex.org/I4210150756 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7300000190734863 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.68677058 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |